A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies

被引：1

作者：

Shah, Nirav N. ^{[1
]}

Krishnan, Amrita Y. ^{[2
]}

Shah, Nina D. ^{[3
]}

Burke, John M. ^{[4
]}

Melear, Jason M. ^{[5
]}

Spira, Alexander I. ^{[6
]}

Kaufman, Jonathan L. ^{[7
]}

Cohen, Jonathon B. ^{[7
]}

Niesvizky, Ruben ^{[8
]}

Popplewell, Leslie L. ^{[2
]}

Chhabra, Saurabh ^{[1
]}

Sharman, Jeff P. ^{[9
]}

Martin, Thomas G. ^{[3
]}

Matheny, Shannon L. ^{[10
]}

Leonard, John P. ^{[8
]}

Molina, Arturo ^{[10
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] City Hope Natl Med Ctr, Duarte, CA USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Rocky Mt Canc Centers, Aurora, CO USA

[5] Texas Oncol, Austin, TX USA

[6] Virginia Canc Specialists, Fairfax, VA USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[8] New York Presbyterian Hosp, Cornell Campus, New York, NY USA

[9] Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA

[10] Sutro Biopharma, San Francisco, CA USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT104

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT104

引用

页数：2

共 50 条

[41] A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Matthew Gumbleton
Stephanie Allan
Hannah Conway
Kenneth Boucher
James Marvin
Josiah Hawks
William Burnett
Matthew Van Brocklin
Jonathan Whisenant
Glynn Gilcrease
Sumati Gupta
BMC Research Notes, 16
[42] Efficacy and safety of 9 MW2821, an antibody-drug conjugate targeting Nectin-4 monotherapy, in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study
Yang, Huijuan
Zhang, Jian
Liu, Rujiao
Gao, Shuiping
Lou, Hanmei
Li, Guiling
Bu, Hualei
Li, Rong
Wang, Shanbing
Shen, Shujing
Zhang, Mingjun
Wang, Peipei
Feng, Zhe
Chu, Nan
GYNECOLOGIC ONCOLOGY, 2024, 190 : S22 - S23
[43] Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Wu, Y.
Jing, H.
Zhang, J.
Cao, X.
Li, K.
Liu, Y.
Meng, M.
Li, H.
Kang, W.
Li, J.
Wang, Q.
Zhu, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1497 - S1497
[44] Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Advani, Ranjana H.
Lebovic, Daniel
Chen, Andy
Brunvand, Mark
Goy, Andre
Chang, Julie E.
Hochberg, Ephraim
Yalamanchili, Sreeni
Kahn, Robert
Lu, Dan
Agarwal, Priya
Dere, Randall C.
Hsieh, Hsin-Ju
Jones, Surai
Chu, Yu-Waye
Cheson, Bruce D.
CLINICAL CANCER RESEARCH, 2017, 23 (05) : 1167 - 1176
[45] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Zhu, Jun
Song, Yuqin
Guo, Ye
Zhou, Keshu
Li, Wenyu
Yang, Yu
Cai, Qingqing
Wang, Zhao
Yang, Haiyan
BLOOD, 2023, 142
[46] Safety, Efficacy, and Pharmacokinetic Profiles of Intravenous Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: A Multicenter, Open-Label Phase I Clinical Study
Ogura, Michinori
Kobayashi, Yukio
Kubonishi, Shiro
Hidaka, Michihiro
Uchida, Toshiki
Takamatsu, Yasushi
BLOOD, 2016, 128 (22)
[47] An open-label, phase II study of intravenous anetumab ravtansine, an anti-mesothelin antibody drug conjugate, in pretreated mesothelin-expressing advanced pancreatic cancer.
Chokshi, Saurin
Hochster, Howard S.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[48] Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody- drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study
Lu, Shun
Jian, Hong
Hong, Wei
Song, Zhengbo
Yang, Nong
Hu, Sheng
Liang, Zibin
Wang, Yongsheng
Wang, Yan
Peng, Min
Yu, Yan
Li, You
Shuang, Jiapeng
Zhao, Kaijing
CANCER RESEARCH, 2023, 83 (08)
[49] Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study
Huinink, Wim W. ten Bokkel
Sufliarsky, Jozef
Smit, Willem M.
Spanik, Stanislav
Wagnerova, Maria
Hirte, Hal W.
Kaye, Stan
Johri, Anandhi R.
Oza, Amit M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3097 - 3103
[50] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
Sun, Yuping
Yu, Jinming
Tolcher, Anthony W.
Albany, Costantine
Chaudhry, Arvind
Dang, Qi
Ye, Leiguang
Yang, Fang
Liu, Baogang
Sun, Longhua
Tang, Jianjun
Xu, Lei
Zhu, Xiangyang
Yang, Yongmin
Yang, Yang
Zhan, Yifan
Li, Benke
Hou, Kexin
Zheng, Yang, Sr.
Wang, Jingjing
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →